The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge

Biomaterials

Volumn 34, Issue 38, 2013, Pages 10305-10318

  Weilhammer, Dina R ^a   Blanchette, Craig D ^a   Fischer, Nicholas O ^a   Alam, Shabnam ^b   Loots, Gabriela G ^a,c   Corzett, Michele ^a   Thomas, Cynthia ^a   Lychak, Cheri ^a   Dunkle, Alexis D ^a   Ruitenberg, Joyce J ^d   Ghanekar, Smita A ^d   Sant, Andrea J ^b   Rasley, Amy ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BD BIOSCIENCES   (United States)

Author keywords

Antimicrobial; Drug delivery; Immunomodulation; Immunostimulation; Nanoparticle

Indexed keywords

ANTIMICROBIAL; CELL SURFACE EXPRESSION; CPG OLIGODEOXYNUCLEOTIDES; HUMAN DENDRITIC CELLS; IMMUNO MODULATIONS; IMMUNOREGULATORY GENES; IMMUNOSTIMULATION; INNATE IMMUNE SYSTEMS;

CELL MEMBRANES; DRUG DELIVERY; GENE EXPRESSION; NANOPARTICLES;

NATURAL LANGUAGE PROCESSING SYSTEMS;

CPG OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; LIPOPROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; NANOPARTICLE; PHOSPHORYL LIPID A; RANTES; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; IN VITRO STUDY; INFLUENZA; INNATE IMMUNITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL; UPREGULATION;

MUS;

ANTIMICROBIAL; DRUG DELIVERY; IMMUNOMODULATION; IMMUNOSTIMULATION; NANOPARTICLE;

ANIMALS; CELL LINE; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA, HUMAN; LIPID A; MALE; MICE; MICE, INBRED BALB C; NANOPARTICLES; OLIGODEOXYRIBONUCLEOTIDES;

EID: 84885375018     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.09.038     Document Type: Article

References (54)

1. Thavaselvam D., Vijayaraghavan R. Biological warfare agents. JPharm Bioallied Sci 2010, 2:179-188.
2. Lu S., Wang S. Technical transformation of biodefense vaccines. Vaccine 2009, 27(Suppl.4):D8-D15.
3. Hackett C.J. Innate immune activation as a broad-spectrum biodefense strategy: prospects and research challenges. JAllergy Clin Immunol 2003, 112:686-694.
4. Amlie-Lefond C., Paz D.A., Connelly M.P., Huffnagle G.B., Dunn K.S., Whelan N.T., et al. Innate immunity for biodefense: a strategy whose time has come. JAllergy Clin Immunol 2005, 116:1334-1342.
5. Treating infectious diseases in a microbial world: report of two workshops on novel antimicrobial therapeutics 2006, The National Academies Press.
6. Beutler B. Innate immunity: an overview. Mol Immunol 2004, 40:845-859.
7. Athman R., Philpott D. Innate immunity via toll-like receptors and nod proteins. Curr Opin Microbiol 2004, 7:25-32.
8. Olive C. Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants. Expert Rev Vaccines 2012, 11:237-256.
9. Parker L.C., Prince L.R., Sabroe I. Translational mini-review series on toll-like receptors: networks regulated by toll-like receptors mediate innate and adaptive immunity. Clin Exp Immunol 2007, 147:199-207.
10. Kanzler H., Barrat F.J., Hessel E.M., Coffman R.L. Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists. Nat Med 2007, 13:552-559.
11. Look M., Bandyopadhyay A., Blum J.S., Fahmy T.M. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Adv Drug Del Rev 2010, 62:378-393.
12. Dunne A., Marshall N.A., Mills K.H.G. Tlr based therapeutics. Curr Opin Pharmocol 2011, 11:404-411.
13. Lembo A., Pelletier M., Iyer R., Timko M., Dudda J.C., West T.E., et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. JImmunol 2008, 180:7574-7581.
14. Cole L.E., Mann B.J., Shirey K.A., Richard K., Yang Y., Gearhart P.J., et al. Role of TLR signaling in francisella tularensis-LPS-induced, antibody-mediated protection against francisella tularensis challenge. JLeukocyte Biol 2011, 90:787-797.
15. Airhart C.L., Rohde H.N., Bohach G.A., Hovde C.J., Deobald C.F., Lee S.S., et al. Induction of innate immunity by lipid a mimetics increases survival from pneumonic plague. Microbiology 2008, 154:2131-2138.
16. Jiang T., Zhao H., Li X.-F., Deng Y.-Q., Liu J., Xu L.-J., et al. CpG oligodeoxynucleotides protect against the 2009 H1N1 pandemic influenza virus infection in a murine model. Antiviral Res 2011, 89:124-126.
17. Judy B.M., Taylor K., Deeraksa A., Johnston R.K., Endsley J.J., Vijayakumar S., et al. Prophylactic application of cpg oligonucleotides augments the early host response and confers protection in acute melioidosis. PLoS ONE 2012, 7:e34176.
18. Juffermans N.P., Leemans J.C., Florquin S., Verbon A., Kolk A.H., Speelman P., et al. Cpg oligodeoxynucleotides enhance host defense during murine tuberculosis. Infect Immun 2002, 70:147-152.
19. Krieg A.M., Love-Homan L., Yi A.-K., Harty J.T. Cpg DNA induces sustained IL-12 expression invivo and resistance to listeria monocytogenes challenge. JImmunol 1998, 161:2428-2434.
20. McCluskie M.J., Cartier J.L.M., Patrick A.J., Sajic D., Weeratna R.D., Rosenthal K.L., et al. Treatment of intravaginal hsv-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (r-848). Antiviral Res 2006, 69:77-85.
21. Wong J.P., Christopher M.E., Viswanathan S., Karpoff N., Dai X., Das D., et al. Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 2009, 27:3481-3483.
22. Zimmermann S., Egeter O., Hausmann S., Lipford G.B., Röcken M., Wagner H., et al. Cutting edge: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. JImmunol 1998, 160:3627-3630.
23. Norton E.B., Clements J.D., Voss T.G., Cárdenas-Freytag L. Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model. JVirol 2010, 84:2983-2995.
24. Klinman D.M., Conover J., Coban C. Repeated administration of synthetic oligodeoxynucleotides expressing CpG motifs provides long-term protection against bacterial infection. Infect Immun 1999, 67:5658-5663.
25. Elkins K.L., Rhinehart-Jones T.R., Stibitz S., Conover J.S., Klinman D.M. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. JImmunol 1999, 162:2291-2298.
26. Bode C., Zhao G., Steinhagen F., Kinjo T., Klinman D.M. CpG DNA as a vaccine adjuvant. Expert Rev Vaccines 2011, 10:499-511.
27. Krishnamachari Y., Geary S., Lemke C., Salem A. Nanoparticle delivery systems in cancer vaccines. Pharm Res 2011, 28:215-236.
28. Jong S., Chikh G., Sekirov L., Raney S., Semple S., Klimuk S., et al. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN. Cancer Immunol Immunother 2007, 56:1251-1264.
29. Harris J., Sharp F.A., Lavelle E.C. The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. Eur J Immunol 2010, 40:634-638.
30. Lin A.Y., Mattos Almeida J.P., Bear A., Liu N., Luo L., Foster A.E., et al. Gold nanoparticle delivery of modified CpG stimulates macrophages and inhibits tumor growth for enhanced immunotherapy. PLoS ONE 2013, 8:e63550.
31. Hamasaki T., Uto T., Akagi T., Akashi M., Baba M. Modulation of gene expression related to toll-like receptor signaling in dendritic cells by poly(γ-glutamic acid) nanoparticles. Clin Vaccine Immunol 2010, 17:748-756.
32. Lung exposure of titanium dioxide nanoparticles induces innate immune activation and long-lasting lymphocyte response in the dark agouti rat. JImmunotoxicol 2011, 8:111-121.
33. Santos D.M., Carneiro M.W., de Moura T.R., Soto M., Luz N.F., Prates D.B., et al. Plga nanoparticles loaded with kmp-11 stimulate innate immunity and induce the killing of leishmania. Nanomed Nanotechnol Biol Med 2013.
34. Shima F., Uto T., Akagi T., Akashi M. Synergistic stimulation of antigen presenting cells via TLR by combining cpg odn and poly(γ-glutamic acid)-based nanoparticles as vaccine adjuvants. Bioconjug Chem 2013, 24:926-933.
35. Li H., Willingham S.B., Ting J.P.-Y., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by nlrp3. JImmunol 2008, 181:17-21.
36. Sharp F.A., Ruane D., Claass B., Creagh E., Harris J., Malyala P., et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the nalp3 inflammasome. Proc Natl Acad Sci U S A 2009, 106:870-875.
37. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
38. Blanchette C., Segelke B., Fischer N., Corzett M., Kuhn E., Cappuccio J., et al. Characterization and purification of polydisperse reconstituted lipoproteins and nanolipoprotein particles. Int J Mol Sci 2009, 10:2958-2971.
39. Blanchette C.D., Law R., Benner W.H., Pesavento J.B., Cappuccio J.A., Walsworth V., et al. Quantifying size distributions of nanolipoprotein particles with single-particle analysis and molecular dynamic simulations. JLipid Res 2008, 49:1420-1430.
40. Fischer N.O., Rasley A., Corzett M., Hwang M.H., Hoeprich P.D., Blanchette C.D. Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. JAm Chem Soc 2013, 135:2044-2047.
41. Ryan R.O. Nanodisks: hydrophobic drug delivery vehicles. Expert Opin Drug Deliv 2008, 5:343-351.
42. Cormode D.P., Chandrasekar R., Delshad A., Briley-Saebo K.C., Calcagno C., Barazza A., et al. Comparison of synthetic high density lipoprotein (HDL) contrast agents for mr imaging of atherosclerosis. Bioconjug Chem 2009, 20:937-943.
43. Bhattacharya P., Grimme S., Ganesh B., Gopisetty A., Sheng J.R., Martinez O., et al. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. JVirol 2010, 84:361-371.
44. Fischer N.O., Blanchette C.D., Chromy B.A., Kuhn E.A., Segelke B.W., Corzett M., et al. Immobilization of his-tagged proteins on nickel-chelating nanolipoprotein particles. Bioconjug Chem 2009, 20:460-465.
45. Blanchette C.D., Fischer N.O., Corzett M., Bench G., Hoeprich P.D. Kinetic analysis of his-tagged protein binding to nickel-chelating nanolipoprotein particles. Bioconjug Chem 2010, 21:1321-1330.
46. Vorauer-Uhl K., Jeschek D., Lhota G., Wagner A., Strobach S., Katinger H. Simultaneous quantification of complex phospholipid compositions containing monophosphoryl lipid-A by RP-HPLC. JLiq Chromatogr Rel Technol 2009, 32:2203-2215.
47. Ray A., Dittel B.N. Isolation of mouse peritoneal cavity cells. JVis Exp 2010, e1488.
48. Lu H., Dietsch G.N., Matthews M.-A.H., Yang Y., Ghanekar S., Inokuma M., et al. Vtx-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC. Clin Cancer Res 2012, 18:499-509.
49. Chan JF-W, Lau SK-P, Woo PC-Y. The emerging novel middle east respiratory syndrome coronavirus: The "knowns" and "unknowns". J Formosan Med Assoc.
50. Leleux J., Roy K. Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective. Adv Healthc Mater 2013, 2:72-94.
51. Demento S.L., Eisenbarth S.C., Foellmer H.G., Platt C., Caplan M.J., Mark Saltzman W., et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009, 27:3013-3021.
52. Stetson D.B., Medzhitov R. Type I interferons in host defense. Immunity 2006, 25:373-381.
53. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
54. Mestas J., Hughes C.C.W. Of mice and not men: differences between mouse and human immunology. JImmunol 2004, 172:2731-2738.